spirapril spirapril spirapril, sold under the brand name renormax among others, is an ace inhibitor antihypertensive drug used to treat hypertension. it belongs to dicarboxy group of ace inhibitors. spiraprilclinical datatrade namesrenormaxahfs/drugs.cominternational drug namespregnancycategory d routes ofadministrationoralatc codec09aa11 (who) legal statuslegal status in general: ℞ (prescription only) pharmacokinetic databioavailability50%metabolismconverted to spiraprilatelimination half-life30 to 35 hoursexcretionhepatic and renalidentifiers iupac name (8s)-7-amino]propanoyl]-1,4-dithia-7-azaspirononane-8-carboxylic acid cas number83647-97-6 ypubchem cid5311447iuphar/bps6575drugbankdb01348 nchemspider4470933 yunii96u2k78i3vkeggd08529 ychebichebi:135756chemblchembl431 ycomptox dashboard (epa)dtxsid1044300 chemical and physical dataformulac22h30n2o5s2molar mass466.61 g·mol−13d model (jsmol)interactive image smiles o=c(occ)(n(c(=o)n2(c(=o)o)cc1(sccs1)c2)c)ccc3ccccc3 inchi inchi=1s/c22h30n2o5s2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23h,3,9-14h2,1-2h3,(h,26,27)/t15-,17-,18-/m0/s1 ykey:hrwcvuifmszdjs-szmvwbnqsa-n y ny (what is this?) (verify) it was patented in 1980 and approved for medical use in 1995. chemistry like many ace inhibitors, this prodrug is converted to the active metabolite spiraprilat following oral administration. unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment. however, data on its effect upon the renal function are conflicting.